Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.3.0.814
Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Operating expenses:        
Research and development $ 1,237,375 $ 4,371,010 $ 4,835,981 $ 9,981,774
General and administrative 721,658 1,627,499 2,498,475 3,301,072
Loss from operations 1,959,033 5,998,509 7,334,456 13,282,846
Nonoperating Income (Expense) [Abstract]        
Change in fair value of warrant liability and Investor Rights Obligation 1,465,422 348,289 1,127,683 734,279
Interest expense, net (197,470) (189,679) (634,772) (983,717)
Total other income (expense) 1,267,952 158,610 492,911 (249,438)
Net loss $ 691,081 $ 5,839,899 $ 6,841,545 $ 13,532,284
Net loss per share of common stock, basic and diluted $ (1.06) $ (9.03) $ (10.53) $ (21.09)
Weighted average shares of Common Stock outstanding, basic and diluted 649,721 646,863 649,721 641,737
Pro forma net loss per share of Common Stock, basic and diluted $ (0.15)   $ (1.48)  
Pro forma weighted average shares of Common Stock outstanding, basic and diluted $ 4,630,143   $ 4,630,143